Moteur de recherche d’entreprises européennes
Financement de l’UE (3 827 031 €) : Evolution des protéines dirigées pour la biologie synthétique et la biocatalyse Hor23/09/2016 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
Evolution des protéines dirigées pour la biologie synthétique et la biocatalyse
ES-Cat will use directed evolution as a tool to reproduce Nature's remarkable ability to generate molecular machines - in particular enzymes – that perform at levels near perfection. Instead of seeing rational and combinatorial approaches as alternatives, we combine them in this network to achieve a ‘smarter’ and more efficient exploration of protein sequence space. By harnessing the forces of Darwinian evolution and design in the laboratory we want to (i) screen large and diverse libraries for proteins with improved and useful functions, (ii) optimize existing proteins for applications in medicine or biotechnology and (iii) provide a better understanding of how existing enzymes evolved and how enzyme mechanisms can be manipulated. This Network brings together leading academic and industrial groups with diverse and complementary skills. The range of methodologies represented in ES-Cat allows an integrated approach combining in silico structural and sequence analysis with experimental high-throughput screening selection methods (phage-, ribozyme and SNAP display, robotic liquid handling, lab-on-a-chip/microfluidics) with subsequent systematic kinetic and biophysical analysis. This integration of methods and disciplines will improve the likelihood of success of directed evolution campaigns, shorten biocatalyst development times, and make protein engineering applicable to a wider range of industrial targets. It will also train the next generation of creative researchers ready to fill roles in tailoring enzymes and other proteins for industrial application in synthetic biology efforts to move towards a bio-based economy, rivaling advances that are being made in the US and allowing the EU economy to harvest its evident socio-economic benefits.
| Alzheimer's Society | ? |
| BEN-GURION UNIVERSITY OF THE NEGEV | 260 301 € |
| Enantis s.r.o. | 232 422 € |
| Fakultni Nemocnice U SV Anny V Brne | 232 422 € |
| Johnson Matthey plc | 273 288 € |
| Medimmune Ltd. | 546 576 € |
| RIJKSUNIVERSITEIT GRONINGEN | 510 749 € |
| The Chancellor Masters and Scholars of the University of Cambridge | 273 288 € |
| UNIVERSITAET GREIFSWALD | 498 433 € |
| UNIVERSITAET MUENSTER | 498 433 € |
| Universite Catholique de Louvain | 501 120 € |
https://cordis.europa.eu/project/id/722610
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel. L’état actuel est présenté à la page suivante : Alzheimer's Society, Londres, Royaume Uni.
